Exposure to rosiglitazone, a PPAR-γ agonist, in late gestation reduces the abundance of factors regulating cardiac metabolism and cardiomyocyte size in the sheep fetus.
about
Exposure to rosiglitazone, a PPAR-γ agonist, in late gestation reduces the abundance of factors regulating cardiac metabolism and cardiomyocyte size in the sheep fetus.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Exposure to rosiglitazone, a P ...... ocyte size in the sheep fetus.
@en
Exposure to rosiglitazone, a P ...... ocyte size in the sheep fetus.
@nl
type
label
Exposure to rosiglitazone, a P ...... ocyte size in the sheep fetus.
@en
Exposure to rosiglitazone, a P ...... ocyte size in the sheep fetus.
@nl
prefLabel
Exposure to rosiglitazone, a P ...... ocyte size in the sheep fetus.
@en
Exposure to rosiglitazone, a P ...... ocyte size in the sheep fetus.
@nl
P2093
P2860
P1476
Exposure to rosiglitazone, a P ...... ocyte size in the sheep fetus.
@en
P2093
Beverly S Muhlhausler
Giuseppe S Posterino
I Caroline McMillen
Kimberley J Botting
Melisa Hui
Shervi Lie
Stacey L Dunn
P2860
P304
P356
10.1152/AJPREGU.00431.2013
P577
2014-01-29T00:00:00Z